{"id":103392,"date":"2024-01-17T08:58:00","date_gmt":"2024-01-17T01:58:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/20240117085800103392"},"modified":"2024-01-18T00:40:06","modified_gmt":"2024-01-17T16:40:06","slug":"%e8%80%90%e7%ab%8b%e5%85%8b%e8%8e%b7%e7%ba%b3%e5%85%a5%e6%9c%80%e6%96%b0%e7%89%88%e7%be%8e%e5%9b%bd%e5%9b%bd%e5%ae%b6%e7%bb%bc%e5%90%88%e7%99%8c%e7%97%87%e7%bd%91%e7%bb%9c%ef%bc%88nccn%ef%bc%89","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/20240117085800103392","title":{"rendered":"\u8010\u7acb\u514b\u83b7\u7eb3\u5165\u6700\u65b0\u7248\u7f8e\u56fd\u56fd\u5bb6\u7efc\u5408\u764c\u75c7\u7f51\u7edc\uff08NCCN\uff09\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u6cbb\u7597\u6307\u5357\uff0c\u518d\u521b\u91cc\u7a0b\u7891\uff01"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/Ascentage_Pharma_Logo-31.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p><span class=\"legendSpanClass\">\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02<\/span><span class=\"legendSpanClass\">2024\u5e741\u670817\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u5df2\u4e8e\u65e5\u524d\u83b7\u7eb3\u5165\u6700\u65b0\u7248\u7f8e\u56fd\u56fd\u5bb6\u7efc\u5408\u764c\u75c7\u7f51\u7edc\uff08NCCN\uff09\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u6cbb\u7597\u6307\u5357<sup>1<\/sup>\uff0c\u8fd9\u6807\u5fd7\u7740\u8010\u7acb\u514b\u8fd9\u4e00&nbsp;\u5168\u7403&quot;Best-in-class&quot;\u836f\u7269\u518d\u83b7\u56fd\u9645\u80bf\u7624\u5b66\u754c\u8ba4\u53ef\uff0c\u4e3a\u5176\u56fd\u9645\u5316\u7684\u53c8\u4e00\u91cd\u5927\u91cc\u7a0b\u7891\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>NCCN\u662f\u7531\u7f8e\u56fd\u591a\u5bb6\u9876\u5c16\u764c\u75c7\u4e2d\u5fc3\u7ec4\u6210\u7684\u975e\u8425\u5229\u6027\u5b66\u672f\u7ec4\u7ec7\uff0c\u5176\u6301\u7eed\u66f4\u65b0\u53d1\u5e03\u7684\u764c\u75c7\u6cbb\u7597\u6307\u5357\u4e0d\u4ec5\u662f\u7f8e\u56fd\u80bf\u7624\u9886\u57df\u4e34\u5e8a\u51b3\u7b56\u7684\u6807\u51c6\uff0c\u4e5f\u5df2\u6210\u4e3a\u5168\u7403\u80bf\u7624\u4e34\u5e8a\u5b9e\u8df5\u4e2d\u5e94\u7528\u6700\u4e3a\u5e7f\u6cdb\u7684\u6307\u5357\u4e4b\u4e00\u3002<\/p>\n<p>\u6b64\u6b21NCCN\u6307\u5357\u5f15\u7528\u4e86\u8010\u7acb\u514b\u4e2d\u56fdI\u671f\u548cII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7597\u6548\u6570\u636e<sup>2<\/sup>\u3002\u5176\u4e2d\uff0c\u8010\u7acb\u514b\u5728CML\u6162\u6027\u671f\uff08-CP\uff09\u548c\u52a0\u901f\u671f\uff08-AP\uff09\u60a3\u8005\u4e2d\u7684\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u7387\uff08MCyR\uff09\u5206\u522b\u4e3a79%\u548c47%\uff0c\u5b8c\u5168\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u7387\uff08CCyR\uff09\u5206\u522b\u4e3a69%\u548c47%\uff0c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\u7387\uff08MMR\uff09\u5206\u522b\u4e3a56%\u548c45%\u3002<\/p>\n<p>\u540c\u65f6\uff0c\u4e34\u5e8a\u6570\u636e\u663e\u793a\u8010\u7acb\u514b\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u5176\u4e0d\u826f\u4e8b\u4ef6\u591a\u4e3a1-2\u7ea7\u4e14\u53ef\u63a7\uff0c\u5176\u4e2d\u5305\u62ec\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\uff0c\u4ee5\u53ca\u4e3b\u8981\u65e0\u75c7\u72b6\u9176\uff08\u5982\u808c\u78f7\u9178\u6fc0\u9176\u3001\u809d\u8f6c\u6c28\u9176\uff09\u5347\u9ad8\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u60a3\u8005\u5728\u63a5\u53d7\u8010\u7acb\u514b\u6cbb\u7597\u7684\u8fc7\u7a0b\u4e2d\uff0c\u672a\u53d1\u751f\u6216\u5f88\u5c11\u53d1\u751f\u52a8\u8109\u95ed\u585e\u53ca\u5176\u4ed6\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u6cbb\u7597\u4e2d\u5e38\u89c1\u7684\u6f5c\u5728\u5242\u91cf\u76f8\u5173\u5e76\u9650\u5236\u6cbb\u7597\u7684\u4e0d\u826f\u53cd\u5e94\u3002<\/p>\n<p>2023\u5e74\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u8010\u7acb\u514b\u591a\u9879\u4e34\u5e8a\u6570\u636e\u663e\u793a\uff0c\u8be5\u836f\u7269\u5728\u524d\u671f\u7ecfTKI\u6df1\u5ea6\u6cbb\u7597\u7684CML\u60a3\u8005\u4ee5\u53ca\u4f34\u6709T315I\u7a81\u53d8\u7684CML\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u548c\u6709\u6548\u6027\u3002\u8fd9\u4e9b\u7814\u7a76\u8868\u660e\uff0c\u4e0e\u6700\u4f73\u53ef\u7528\u7597\u6cd5\uff08Best Available Therapy, BAT\uff1b\u5305\u62ec\u4f0a\u9a6c\u66ff\u5c3c\u3001\u8fbe\u6c99\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u7b49\uff09<sup>3<\/sup>\u5bf9\u7167\u7ec4\u76f8\u6bd4\uff0c\u8010\u7acb\u514b\u663e\u8457\u5ef6\u957f\u4e86\u60a3\u8005\u7684\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\uff0c\u51cf\u5c11\u4e8660%\u7684\u4e8b\u4ef6\u98ce\u9669\uff1b\u6b64\u5916\uff0c\u8010\u7acb\u514b\u5728\u7ecf\u7b2c\u4e09\u4ee3TKI ponatinib\u6216\u53d8\u6784\u6291\u5236\u5242asciminib\u6cbb\u7597\u5931\u8d25\u7684\u60a3\u8005\u4e2d\u6cbb\u7597\u6f5c\u529b\u663e\u8457\u3002<sup>4<\/sup><\/p>\n<p>\u8010\u7acb\u514b\u662f\u4e9a\u76db\u533b\u836f\u539f\u521b1\u7c7b\u65b0\u836f\uff0c\u4e3a\u5168\u7403\u5c42\u9762&quot;Best-in-class&quot;\u836f\u7269\u3002\u4f5c\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u8010\u7acb\u514b\u5bf9BCR-ABL\u4ee5\u53ca\u5305\u62ecT315I\u7a81\u53d8\u5728\u5185\u7684\u591a\u79cdBCR-ABL\u7a81\u53d8\u4f53\u6709\u7a81\u51fa\u6548\u679c\u30022021\u5e7411\u6708\uff0c\u8010\u7acb\u514b\u9996\u4e2a\u9002\u5e94\u75c7\u83b7\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u4e8e\u6cbb\u7597\u4efb\u4f55TKI\u8010\u836f\u3001\u5e76\u4f34\u6709T315I\u7a81\u53d8\u7684CML-CP\u6216CML-AP\u6210\u5e74\u60a3\u8005\u30022023\u5e7411\u6708\uff0c\u8010\u7acb\u514b\u65b0\u9002\u5e94\u75c7\u83b7\u6279\uff0c\u7528\u4e8e\u6cbb\u7597\u5bf9\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8010\u7acb\u514b\u5728\u4e2d\u56fd\u7684\u5546\u4e1a\u5316\u63a8\u5e7f\u7531\u4e9a\u76db\u533b\u836f\u548c\u4fe1\u8fbe\u751f\u7269\u5171\u540c\u8d1f\u8d23\u3002<\/p>\n<p><b>\u4e9a\u76db\u533b\u836f\u8463\u4e8b\u957f\u3001<\/b><b>CEO<\/b><b>\u6768\u5927\u4fca\u535a\u58eb\u8868\u793a<\/b>\uff1a&quot;\u6b64\u6b21\u8010\u7acb\u514b\u83b7\u7eb3\u5165NCCN\u6307\u5357\u662f\u8be5\u836f\u7269\u7684\u53c8\u4e00\u56fd\u9645\u5316\u91cc\u7a0b\u7891\u4e8b\u4ef6\uff0c\u6807\u5fd7\u7740\u8010\u7acb\u514b\u518d\u83b7\u5168\u7403\u80bf\u7624\u5b66\u754c\u7684\u91cd\u8981\u8ba4\u53ef\u3002\u5373\u4f7f\u662f\u5728\u590d\u53d1\/\u96be\u6cbb\u7684CML\u60a3\u8005\u4e2d\uff0c\u8010\u7acb\u514b\u4e5f\u4f9d\u7136\u5b89\u5168\u6709\u6548\uff0c\u7ed9\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u5e26\u6765\u4e86\u6539\u5584\uff0c\u8fd9\u4ee4\u6211\u4eec\u5907\u53d7\u9f13\u821e\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u8df5\u884c&nbsp;\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42&#8217;\u7684\u4f7f\u547d\uff0c\u7ee7\u7eed\u52a0\u901f\u63a8\u8fdb\u8010\u7acb\u514b\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u4ece\u800c\u60e0\u53ca\u66f4\u591a\u60a3\u8005\u3002&quot;<\/p>\n<p><b>\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a<\/b>\uff1a&quot;\u7ee7ASH\u53e3\u5934\u62a5\u544a\u516d\u8fde\u51a0\u4e4b\u540e\uff0c\u6b64\u6b21\u8010\u7acb\u514b<sup>&reg;<\/sup>\u83b7\u7eb3\u5165NCCN\u6307\u5357\uff0c\u518d\u6b21\u9a8c\u8bc1\u4e86\u8be5\u4ea7\u54c1\u622a\u81f3\u76ee\u524d\u5df2\u53d6\u5f97\u7684\u4ee4\u4eba\u632f\u594b\u7684\u7814\u7a76\u6210\u679c\u3002\u8fd9\u8ba9\u6211\u4eec\u65e0\u6bd4\u6fc0\u52a8\uff01\u672a\u6765\uff0c\u6211\u4eec\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u516c\u53f8\u5728\u7814\u54c1\u79cd\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u4ece\u800c\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7597\u65b9\u6848\uff1b\u5e76\u4e0d\u65ad\u62d3\u5c55\u8010\u7acb\u514b\u5728\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u7b49\u66f4\u591a\u9002\u5e94\u75c7\u9886\u57df\u7684\u4e34\u5e8a\u6f5c\u529b\uff0c\u8ba9\u66f4\u591a\u60a3\u8005\u83b7\u76ca\uff01&quot;<\/p>\n<p><b>\u53c2\u8003\u6587\u732e<\/b><\/p>\n<ol type=\"1\">\n<li>Shah N, Bhatia R<i>, <\/i>Altman JK et al.<i>&nbsp; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&reg;) Chronic Myeloid Leukemia Version 2.2024<\/i> (<span class=\"xn-chron\">December 5, 2023<\/span>). Available from: <a href=\"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf<\/a>.&nbsp;<br \/>Accessed <span class=\"xn-chron\">January 10, 2024<\/span>.<\/li>\n<li>Jiang Q, Li Z, Qin Y et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial.&nbsp;<i>J Hematol Oncol<\/i> 2022;15:113.&nbsp;<\/li>\n<li>Jiang Q, Li Z, Zhang G, et al. Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia chronic-phase (CML-CP) in a registrational randomized phase 2 study. Blood 2023;142(Suppl 1):869<\/li>\n<li>Jabbour E, Kantarjian H, Koller PB et al. Update of olverembatinib (HQP1351) overcoming ponatinib and\/or Asciminib resistance in patients (pts) with heavily pretreated\/refractory chronic myeloid leukemia (CML) and <span class=\"xn-location\">Philadelphia<\/span> chromosome-positive acute lymphoblastic leukemia (Ph<sup>+<\/sup> ALL). <i>Blood<\/i> 2023;142 (Suppl 1):1798.<\/li>\n<\/ol>\n<p><b><u>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/u><\/b><\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67099\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216&nbsp;MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5540\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n<p>\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u5df2\u88ab\u6210\u529f\u7eb3\u5165\u300a\u56fd\u5bb6\u57fa\u672c\u533b\u7597\u4fdd\u9669\u3001\u5de5\u4f24\u4fdd\u9669\u548c\u751f\u80b2\u4fdd\u9669\u836f\u54c1\u76ee\u5f55(2022\u5e74)\u300b\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3001\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002<\/p>\n<p>\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9716\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d&quot;\u91cd\u5927\u65b0\u836f\u521b\u5236&quot;\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879&quot;\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730&quot;\u53ca4\u9879&quot;\u521b\u65b0\u836f\u7269\u7814\u53d1&quot;\uff0c\u53e6\u5916\u627f\u62c5&quot;\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb&quot;\u4e13\u98791\u9879\u3002<\/p>\n<p>\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c&quot;\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42&quot;\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p><b><u>\u524d\u77bb\u6027\u58f0\u660e<\/u><\/b><\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8<span id=\"spanHghlt6c8a\">\u3002<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022024\u5e741\u670817\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u521b1\u7c7b\u65b0\u836f\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u5df2\u4e8e\u65e5\u524d\u83b7\u7eb3\u5165\u6700\u65b0\u7248\u7f8e\u56fd\u56fd\u5bb6\u7efc\u5408\u764c\u75c7\u7f51\u7edc\uff08NCCN\uff09\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u6cbb\u7597\u6307\u53571\uff0c\u8fd9\u6807\u5fd7\u7740\u8010\u7acb\u514b\u8fd9\u4e00&nbsp;\u5168\u7403&quot;Best-in-class&quot;\u836f\u7269\u518d\u83b7\u56fd\u9645\u80bf\u7624\u5b66\u754c\u8ba4\u53ef\uff0c\u4e3a\u5176\u56fd\u9645\u5316\u7684\u53c8\u4e00\u91cd\u5927\u91cc\u7a0b\u7891\u3002 NCCN\u662f\u7531\u7f8e\u56fd\u591a\u5bb6\u9876\u5c16\u764c\u75c7\u4e2d\u5fc3\u7ec4\u6210\u7684\u975e\u8425\u5229\u6027\u5b66\u672f\u7ec4\u7ec7\uff0c\u5176\u6301\u7eed\u66f4\u65b0\u53d1\u5e03\u7684\u764c\u75c7\u6cbb\u7597\u6307\u5357\u4e0d\u4ec5\u662f\u7f8e\u56fd\u80bf\u7624\u9886\u57df\u4e34\u5e8a\u51b3\u7b56\u7684\u6807\u51c6\uff0c\u4e5f\u5df2\u6210\u4e3a\u5168\u7403\u80bf\u7624\u4e34\u5e8a\u5b9e\u8df5\u4e2d\u5e94\u7528\u6700\u4e3a\u5e7f\u6cdb\u7684\u6307\u5357\u4e4b\u4e00\u3002 \u6b64\u6b21NCCN\u6307\u5357\u5f15\u7528\u4e86\u8010\u7acb\u514b\u4e2d\u56fdI\u671f\u548cII\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7597\u6548\u6570\u636e2\u3002\u5176\u4e2d\uff0c\u8010\u7acb\u514b\u5728CML\u6162\u6027\u671f\uff08-CP\uff09\u548c\u52a0\u901f\u671f\uff08-AP\uff09\u60a3\u8005\u4e2d\u7684\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u7387\uff08MCyR\uff09\u5206\u522b\u4e3a79%\u548c47%\uff0c\u5b8c\u5168\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u7387\uff08CCyR\uff09\u5206\u522b\u4e3a69%\u548c47%\uff0c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\u7387\uff08MMR\uff09\u5206\u522b\u4e3a56%\u548c45%\u3002 \u540c\u65f6\uff0c\u4e34\u5e8a\u6570\u636e\u663e\u793a\u8010\u7acb\u514b\u5177\u6709\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u5176\u4e0d\u826f\u4e8b\u4ef6\u591a\u4e3a1-2\u7ea7\u4e14\u53ef\u63a7\uff0c\u5176\u4e2d\u5305\u62ec\u8840\u5c0f\u677f\u51cf\u5c11\u3001\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\uff0c\u4ee5\u53ca\u4e3b\u8981\u65e0\u75c7\u72b6\u9176\uff08\u5982\u808c\u78f7\u9178\u6fc0\u9176\u3001\u809d\u8f6c\u6c28\u9176\uff09\u5347\u9ad8\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u60a3\u8005\u5728\u63a5\u53d7\u8010\u7acb\u514b\u6cbb\u7597\u7684\u8fc7\u7a0b\u4e2d\uff0c\u672a\u53d1\u751f\u6216\u5f88\u5c11\u53d1\u751f\u52a8\u8109\u95ed\u585e\u53ca\u5176\u4ed6\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u6cbb\u7597\u4e2d\u5e38\u89c1\u7684\u6f5c\u5728\u5242\u91cf\u76f8\u5173\u5e76\u9650\u5236\u6cbb\u7597\u7684\u4e0d\u826f\u53cd\u5e94\u3002 2023\u5e74\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\u5c55\u793a\u7684\u8010\u7acb\u514b\u591a\u9879\u4e34\u5e8a\u6570\u636e\u663e\u793a\uff0c\u8be5\u836f\u7269\u5728\u524d\u671f\u7ecfTKI\u6df1\u5ea6\u6cbb\u7597\u7684CML\u60a3\u8005\u4ee5\u53ca\u4f34\u6709T315I\u7a81\u53d8\u7684CML\u60a3\u8005\u4e2d\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u548c\u6709\u6548\u6027\u3002\u8fd9\u4e9b\u7814\u7a76\u8868\u660e\uff0c\u4e0e\u6700\u4f73\u53ef\u7528\u7597\u6cd5\uff08Best Available Therapy, BAT\uff1b\u5305\u62ec\u4f0a\u9a6c\u66ff\u5c3c\u3001\u8fbe\u6c99\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u7b49\uff093\u5bf9\u7167\u7ec4\u76f8\u6bd4\uff0c\u8010\u7acb\u514b\u663e\u8457\u5ef6\u957f\u4e86\u60a3\u8005\u7684\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\uff0c\u51cf\u5c11\u4e8660%\u7684\u4e8b\u4ef6\u98ce\u9669\uff1b\u6b64\u5916\uff0c\u8010\u7acb\u514b\u5728\u7ecf\u7b2c\u4e09\u4ee3TKI ponatinib\u6216\u53d8\u6784\u6291\u5236\u5242asciminib\u6cbb\u7597\u5931\u8d25\u7684\u60a3\u8005\u4e2d\u6cbb\u7597\u6f5c\u529b\u663e\u8457\u30024 \u8010\u7acb\u514b\u662f\u4e9a\u76db\u533b\u836f\u539f\u521b1\u7c7b\u65b0\u836f\uff0c\u4e3a\u5168\u7403\u5c42\u9762&quot;Best-in-class&quot;\u836f\u7269\u3002\u4f5c\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u8010\u7acb\u514b\u5bf9BCR-ABL\u4ee5\u53ca\u5305\u62ecT315I\u7a81\u53d8\u5728\u5185\u7684\u591a\u79cdBCR-ABL\u7a81\u53d8\u4f53\u6709\u7a81\u51fa\u6548\u679c\u30022021\u5e7411\u6708\uff0c\u8010\u7acb\u514b\u9996\u4e2a\u9002\u5e94\u75c7\u83b7\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u4e8e\u6cbb\u7597\u4efb\u4f55TKI\u8010\u836f\u3001\u5e76\u4f34\u6709T315I\u7a81\u53d8\u7684CML-CP\u6216CML-AP\u6210\u5e74\u60a3\u8005\u30022023\u5e7411\u6708\uff0c\u8010\u7acb\u514b\u65b0\u9002\u5e94\u75c7\u83b7\u6279\uff0c\u7528\u4e8e\u6cbb\u7597\u5bf9\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u836f\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8010\u7acb\u514b\u5728\u4e2d\u56fd\u7684\u5546\u4e1a\u5316\u63a8\u5e7f\u7531\u4e9a\u76db\u533b\u836f\u548c\u4fe1\u8fbe\u751f\u7269\u5171\u540c\u8d1f\u8d23\u3002 \u4e9a\u76db\u533b\u836f\u8463\u4e8b\u957f\u3001CEO\u6768\u5927\u4fca\u535a\u58eb\u8868\u793a\uff1a&quot;\u6b64\u6b21\u8010\u7acb\u514b\u83b7\u7eb3\u5165NCCN\u6307\u5357\u662f\u8be5\u836f\u7269\u7684\u53c8\u4e00\u56fd\u9645\u5316\u91cc\u7a0b\u7891\u4e8b\u4ef6\uff0c\u6807\u5fd7\u7740\u8010\u7acb\u514b\u518d\u83b7\u5168\u7403\u80bf\u7624\u5b66\u754c\u7684\u91cd\u8981\u8ba4\u53ef\u3002\u5373\u4f7f\u662f\u5728\u590d\u53d1\/\u96be\u6cbb\u7684CML\u60a3\u8005\u4e2d\uff0c\u8010\u7acb\u514b\u4e5f\u4f9d\u7136\u5b89\u5168\u6709\u6548\uff0c\u7ed9\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u5e26\u6765\u4e86\u6539\u5584\uff0c\u8fd9\u4ee4\u6211\u4eec\u5907\u53d7\u9f13\u821e\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u8df5\u884c&nbsp;\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42&#8217;\u7684\u4f7f\u547d\uff0c\u7ee7\u7eed\u52a0\u901f\u63a8\u8fdb\u8010\u7acb\u514b\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u4ece\u800c\u60e0\u53ca\u66f4\u591a\u60a3\u8005\u3002&quot; \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a&quot;\u7ee7ASH\u53e3\u5934\u62a5\u544a\u516d\u8fde\u51a0\u4e4b\u540e\uff0c\u6b64\u6b21\u8010\u7acb\u514b&reg;\u83b7\u7eb3\u5165NCCN\u6307\u5357\uff0c\u518d\u6b21\u9a8c\u8bc1\u4e86\u8be5\u4ea7\u54c1\u622a\u81f3\u76ee\u524d\u5df2\u53d6\u5f97\u7684\u4ee4\u4eba\u632f\u594b\u7684\u7814\u7a76\u6210\u679c\u3002\u8fd9\u8ba9\u6211\u4eec\u65e0\u6bd4\u6fc0\u52a8\uff01\u672a\u6765\uff0c\u6211\u4eec\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u516c\u53f8\u5728\u7814\u54c1\u79cd\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u4ece\u800c\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7597\u65b9\u6848\uff1b\u5e76\u4e0d\u65ad\u62d3\u5c55\u8010\u7acb\u514b\u5728\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u7b49\u66f4\u591a\u9002\u5e94\u75c7\u9886\u57df\u7684\u4e34\u5e8a\u6f5c\u529b\uff0c\u8ba9\u66f4\u591a\u60a3\u8005\u83b7\u76ca\uff01&quot; \u53c2\u8003\u6587\u732e Shah N, Bhatia R, Altman JK et al.&nbsp; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines&reg;) Chronic Myeloid Leukemia Version 2.2024 (December 5, 2023). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf.&nbsp;Accessed January 10, 2024. Jiang Q, Li Z, Qin Y et al. Olverembatinib&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/20240117085800103392\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":103395,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-103392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/103392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=103392"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/103392\/revisions"}],"predecessor-version":[{"id":103394,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/103392\/revisions\/103394"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/103395"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=103392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=103392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=103392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}